In this free webinar, learn how vibration-controlled transient elastography (VCTE) is advancing metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) management and reducing the liver disease burden. The featured speakers will discuss the ESSENCE/SYMMETRY trials and other longitudinal studies and how they highlight significant progress in non-invasive diagnostics for MASLD/MASH. Attendees will obtain valuable knowledge on how the findings from non-invasive tests can be applied in clinical practice, enhancing the ability to make informed decisions.
TORONTO, June 16, 2025 /PRNewswire-PRWeb/ -- Are you ready to use non-invasive testing to unlock the potential in metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) management?
Join the featured speakers for this webinar that will transform your understanding of non-invasive diagnostic tests. This session offers an unparalleled opportunity to delve into the latest advancements, with expert insights from pivotal MASLD/MASH clinical trials, including the ESSENCE and SYMMETRY trials, as well as key longitudinal studies. Reserve your spot today!
MASLD/MASH is a condition marked by the accumulation of fat in the liver, which can progress to more serious liver aliments including fibrosis, cirrhosis and hepatocellular carcinoma. The increasing prevalence of liver diseases worldwide necessitates the development of effective, non-invasive diagnostic techniques.
Diagnosis of MASLD/MASH can be challenging due to its subtle early symptoms and the invasiveness of traditional diagnostic techniques such as biopsies. Recent advancements in non-invasive tests offer promising alternatives for more accessible and accurate diagnosis, which are crucial for timely treatment and management.
This webinar will focus on the latest advancements and findings in non-invasive diagnostic methods for MASLD/MASH as well as insights gained from the ESSENCE/SYMMETRY trials and groundbreaking longitudinal studies.
Monitoring liver stiffness is important for assessing the progression and the future risk of liver-related events in patients with MASH. Vibration-controlled transient elastography (VCTE) has emerged as a valuable non-invasive tool for measuring liver stiffness. Increases and decreases in liver stiffness measurements may be independently associated with the risk of liver-related events in MASLD/MASH.
Elevated liver stiffness indicates the presence of fibrosis, which is a critical marker for predicting adverse liver outcomes. Conversely, a decrease in liver stiffness may suggest improvement in liver health, potentially due to lifestyle changes and/or therapeutic interventions. Both single and serial measurements of VCTE-based scores may play an important role in early detection, risk stratification, monitoring treatment response and guiding clinical decisions. Join the speakers to explore how VCTE impacts MASLD/MASH management and the liver disease burden.
The ESSENCE trial represents a significant step forward in non-invasive diagnostics for MASH, with a discussion on the clinical implications of these findings. As non-invasive tests for MASH become increasingly reliable and widespread, they have the potential to transform the approach in the diagnosis and management of MASLD/MASH.
Register for this webinar to stay ahead in the field of liver disease management. This webinar promises to be a valuable experience for healthcare professionals, researchers and anyone interested in the advancements of MASLD/MASH clinical trials. We invite you to join the speakers as they explore these groundbreaking insights and discuss their implications for the future of healthcare.
Join Naim Alkhouri, MD, Chief Academic Officer, Summit Clinical Research; Dr. Mazen Noureddin, MD, MHSc, Chief Scientific Officer, Summit Clinical Research; and Samer Gawrieh, MD, Professor of Clinical Medicine, Indiana University School of Medicine, for the live webinar on Monday, June 30, 2025, at 12pm EDT (5pm BST/UK).
For more information, or to register for this event, visit Advancing MASLD/MASH Clinical Trials: The Role of Non-Invasive Diagnostics.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], www.xtalks.com
SOURCE Xtalks
Share this article